StockNews.AI
QTI
StockNews.AI
33 days

QT Imaging Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy

1. QT Imaging launches QTviewer 2.8 enhancing breast imaging technologies. 2. New features improve usability for radiologists and promote disease monitoring. 3. Company aims to transform into a precision imaging AI enterprise. 4. Release expected to drive growth through innovation and clinical partnerships. 5. QTviewer integrates AI tools for future enhancements and efficiency.

8m saved
Insight
Article

FAQ

Why Bullish?

The launch of QTviewer 2.8 signals technological advancement, potentially attracting investor interest. Historically, similar announcements have positively influenced stock prices in tech-focused medical device firms like QTI.

How important is it?

The launch of QTviewer 2.8 is a major event that highlights QTI's commitment to innovation and could affect pricing positively as it appeals to potential users in the healthcare sector.

Why Short Term?

Initial market reactions may occur swiftly due to the product's direct relevance to current imaging needs. This aligns with historical trends where tech updates correlate with immediate price shifts.

Related Companies

GESIENSYK
- NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce the launch of its latest QTviewer™, version 2.8. QTviewer stores and displays the QTscan™ images generated by the Company’s U.S. FDA-cleared QTI Breast Acoustic CT™ scanner, the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation — setting a new standard for safe and repeatable monitoring. Key features of QTviewer 2.8 include: Effortless, Stateless DICOM (Digital Imaging and Communications in Medicine) Viewing: QTviewer 2.8 enables instant access to QTscan studies without a preconfigured database — ideal for remote reads, portable drives, or low-resource environments. This also supports direct PACS (Picture Archiving and Communication System) integration where available. Real-Time Lesion Doubling Time Analysis: Integrated tool allows clinicians to assess lesion growth within the standard reading workflow — enhancing monitoring of disease progression or treatment response. Unlike conventional methods, QTI’s technology enables fully quantitative, volumetric analysis without the need for contrast agents or ionizing radiation. New RGB Visualization Modes: Enables interpretation of both anatomical structures and quantitative data, supporting diagnostic and research use cases alike. The RGB mode incorporates speed of sound mapping, providing additional visual representation of tissue composition and imaging findings — an essential capability for advancing our research into lesion characterization and AI-driven classification. Advanced Multi-Series Comparison: Radiologists can now view multiple series from the same study in parallel windows, improving anatomical and temporal comparisons. Optimized Viewport Layouts for Radiology Workstations: Vertical orientation and multi-monitor support improve ergonomics and diagnostic clarity for stackable and long-axis views. Secure License Management for Enterprise Use: PC-based license key verification ensures secure, compliant deployment across hospital and academic systems. Improved Stability & Usability: Backend upgrades streamline loading, enhance compatibility, and support quick launches from file associations or command line; and Reinforced Diagnostic Workflow: QTviewer 2.8 provides automatic recognition of image types, such as speed-of-sound, attenuation, and reflection, ensuring seamless workflow and consistent interpretation. “This is an exciting time for our team as we enter into a period of anticipated rapid growth, driven by continuous innovation like our recent release of image reconstruction software, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency, and this enhanced generation of QTviewer,” said QTI’s Chief Science Officer, Dr. Bilal Malik. “By providing radiologists and clinical partners with a growing portfolio of enabling, intuitive support tools, QTI aims to expand access to medical imaging while ensuring superior patient experience and improving health outcomes.” Transforming QTI into a precision imaging AI company is a key pillar of the Company’s growth strategy. To that end, beyond today’s announcement, the QTI team continues to innovate by not only developing proprietary AI/ML tools designed to accelerate image processing and reduce scanning time, but also conducting AI/ML projects which will be viewed/integrated in the QTviewer in the future. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com. Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of QTviewer and the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including transforming it into a precision imaging AI company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, clinical studies, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement. More News From QT Imaging Holdings, Inc.

Related News